Tianjin-based biotech Protein T, focused on multi-omics research, has reportedly raised close to RMB 100 million (USD 14.7 million) in a Series A financing round. The sole investor was Shanghai Dinghui Baifu Wealth Management. The proceeds will be used to facilitate Protein T’s business expansion, strategic layout, and the translation and application of innovative technologies.
Company Background and Pipeline
Founded in 2014, Protein T has a product pipeline that covers multiple therapeutic areas, including lung cancer and liver cancer. Several products are currently being prepared for regulatory filing. The company has also established intellectual property across seven key areas: sample preparation, auxiliary materials, mass spectrometry, data analysis, and clinical application.
Future Outlook
The Series A funding round positions Protein T to accelerate its business growth and expand its multi-omics-focused product pipeline. With a strong focus on innovation and strategic development, Protein T aims to become a leading player in the biotech industry.-Fineline Info & Tech
